# An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

> **NCT00132925** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 460 (—)

## Conditions studied

- Rhinitis, Allergic, Perennial

## Interventions

- **DRUG:** Triamcinolone

## Key facts

- **NCT ID:** NCT00132925
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 460 (—)
- **Last updated:** 2011-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132925, "An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00132925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*